U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Internal Radioactive Contamination —Development of Decorporation Agents
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Internal Radioactive Contamination —Development of Decorporation Agents March 2006

Download the Final Guidance Document Read the Federal Register Notice
Final
Docket Number:
FDA-2005-D-0025
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

This document provides guidance to industry on the development of decorporation agents for which evidence is needed to demonstrate effectiveness but for which human efficacy studies are unethical or infeasible. In such instances, the Animal Efficacy Rule, 21 CFR part 314 subpart I, may be invoked to approve new decorporation agents not previously marketed or new indications for previously marketed drug products. Specifically, this document provides guidance on (1) chemistry, manufacturing, and controls (CMC) information; (2) animal efficacy, safety pharmacology, and toxicology studies; (3) clinical pharmacology, biopharmaceutics, and human safety studies; and (4) postapproval commitments, for such drug products.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2005-D-0025.

Back to Top